구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | stem cells |
Overview Company | Genzyme, a Sanofi Company |
Overview Modality | CGT |
Overview Target | Acute Lymphoblastic Leukemia |
Overview Indication | Acute Lymphoblastic Leukemia; Acute Myelocytic Leukemia |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Vector | lentiviral barcoded library |
MoA Mechanism | targeting the STAT3 pathway |
MoA Biomarker | biomarker changes following a single intrathecal injection of autologous bone marrow-derived mesenchymal stem |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | tumor growth inhibition |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Safety and preliminary efficacy of autologous bone marrow-derived mesenchymal stem cell transplantation in hereditary cerebellar ataxia: phase I/IIa clinical trial.. Hereditary cerebellar ataxias (HCA) encompass a spectrum of pathological conditions affecting the cerebellum. Currently, there is growing interest in the potential role of mesenchymal stem cells (MSCs) as an investigational therapeuti… |
Clinical Safety signal | Safety and preliminary efficacy of autologous bone marrow-derived mesenchymal stem cell transplantation in hereditary cerebellar ataxia: phase I/IIa clinical trial.. Hereditary cerebellar ataxias (HCA) encompass a spectrum of pathological conditions affecting the cerebellum. Currently, there is growing interest in the potential role of mesenchymal stem cells (MSCs) as an investigational therapeuti… |
Clinical Reported PFS | 35.5 |
Clinical Reported OS | 68 |
Clinical Result source | ClinicalTrials.gov NCT02208037 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT02208037 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | stem cells |
Overview Company | Genzyme, a Sanofi Company |
Overview Modality | CGT |
Overview Target | Acute Lymphoblastic Leukemia |
Overview Indication | Acute Lymphoblastic Leukemia; Acute Myelocytic Leukemia |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Vector | lentiviral barcoded library |
MoA Mechanism | targeting the STAT3 pathway |
MoA Biomarker | biomarker changes following a single intrathecal injection of autologous bone marrow-derived mesenchymal stem |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | tumor growth inhibition |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Safety and preliminary efficacy of autologous bone marrow-derived mesenchymal stem cell transplantation in hereditary cerebellar ataxia: phase I/IIa clinical trial.. Hereditary cerebellar ataxias (HCA) encompass a spectrum of pathological conditions affecting the cerebellum. Currently, there is growing interest in the potential role of mesenchymal stem cells (MSCs) as an investigational therapeuti… |
Clinical Safety signal | Safety and preliminary efficacy of autologous bone marrow-derived mesenchymal stem cell transplantation in hereditary cerebellar ataxia: phase I/IIa clinical trial.. Hereditary cerebellar ataxias (HCA) encompass a spectrum of pathological conditions affecting the cerebellum. Currently, there is growing interest in the potential role of mesenchymal stem cells (MSCs) as an investigational therapeuti… |
Clinical Reported PFS | 35.5 |
Clinical Reported OS | 68 |
Clinical Result source | ClinicalTrials.gov NCT02208037 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT02208037 |
추천 비교
추천 비교